The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer

被引:101
作者
Bott, Simon R. J. [1 ]
Ahmed, Hashim U. [2 ]
Hindley, Richard G. [3 ]
Abdul-Rahman, Ahmad [2 ]
Freeman, Alex [4 ]
Emberton, Mark [2 ]
机构
[1] Frimley Pk Hosp NHS Fdn Trust, London, England
[2] UCL, Div Surg & Intervent Sci, London, England
[3] N Hampshire & Basingstoke NHS Fdn Trust, Surrey, England
[4] Univ Coll Hosp NIHR Comprehens Biomed Res Ctr, Dept Histopathol, London, England
关键词
prostate cancer; risk stratification; multifocal; index lesion; focal therapy; RADICAL PROSTATECTOMY; PREDICT; RECURRENCE; BIOPSIES; EXTENT; MEN;
D O I
10.1111/j.1464-410X.2010.09436.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
OBJECTIVE To determine the pathological characteristics of radical prostatectomy specimens with respect to index and secondary lesions. METHODS A total of 100 consecutive radical prostatectomy specimens examined at a single hospital were assessed. Patients undergoing salvage prostatectomy or those who had received neoadjuvant hormonal manipulation were excluded. Preoperative data and the number, volume and Gleason grade of each tumour focus were recorded. Criteria used to define a clinically significant lesion were tumour volume >= 0.5 mL and/or Gleason pattern 4 or 5 and/or extra-capsular disease. RESULTS Overall, 374 foci were examined. The median number of tumours per patient was 3.5 (range 1-15). The overall median tumour volume was 1.4 mL (range 0.1-18.2), the median volume of the largest (index) tumour was 0.95 mL (range 0.1-18.2) and the median volume of the largest secondary tumour was 0.2 mL (range 0.05-1.7). There were no patients in whom the index lesion was insignificant and secondary tumours were significant (by grade or extra-capsular disease). Seventy-seven fulfilled the clinical parameters of low-to-intermediate-risk disease. If focal therapy can be delivered with the aim of ablating all clinically significant disease, with untreated areas harbouring no cancer or clinically insignificant disease, between 58.5 and 67.5% might have been suitable for such a strategy. CONCLUSIONS The proportion of men with low-to-intermediate-risk prostate cancer who may potentially be suitable for a focal therapy approach is unknown. The key question is whether the volume of individual lesions points to clinically significant cancer and whether ablation of these lesions alone would lead to cancer control. This research question is currently undergoing evaluation within a prospective clinical trial.
引用
收藏
页码:1607 / 1611
页数:5
相关论文
共 21 条
[1]
Is it time to consider a role for MRI before prostate biopsy? [J].
Ahmed, Hashim U. ;
Kirkham, Alex ;
Arya, Manit ;
Illing, Rowland ;
Freeman, Alex ;
Allen, Clare ;
Emberton, Mark .
NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (04) :197-206
[2]
Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way? [J].
Ahmed, Hashim Uddin ;
Emberton, Mark .
WORLD JOURNAL OF UROLOGY, 2008, 26 (05) :457-467
[3]
Will focal therapy become a standard of care for men with localized prostate cancer? [J].
Ahmed, Hashim Uddin ;
Pendse, Doug ;
Illing, Rowland ;
Allen, Clare ;
van der Meulen, Jan H. P. ;
Emberton, Mark .
NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (11) :632-642
[4]
The Index Lesion and the Origin of Prostate Cancer [J].
Ahmed, Hashim Uddin .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (17) :1704-1706
[5]
Radical prostatectomy: pathology compared with other major series findings in 1001 cases and over time [J].
Bott, SRJ ;
Freeman, AA ;
Stenning, S ;
Cohen, J ;
Parkinson, MC .
BJU INTERNATIONAL, 2005, 95 (01) :34-39
[6]
Anterior prostate cancer: is it more difficult to diagnose? [J].
Bott, SRJ ;
Young, MPA ;
Kellett, MJ ;
Parkinson, MC .
BJU INTERNATIONAL, 2002, 89 (09) :886-889
[7]
THE VOLUME OF PROSTATE-CANCER IN THE BIOPSY SPECIMEN CANNOT RELIABLY PREDICT THE QUANTITY OF CANCER IN THE RADICAL PROSTATECTOMY SPECIMEN ON AN INDIVIDUAL BASIS [J].
CUPP, MR ;
BOSTWICK, DG ;
MYERS, RP ;
OESTERLING, JE .
JOURNAL OF UROLOGY, 1995, 153 (05) :1543-1548
[8]
Djavan B, 1999, Tech Urol, V5, P139
[9]
Eggener SE, 2007, J UROLOGY, V178, P2260, DOI 10.1016/j.juro.2007.08.072
[10]
PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER [J].
EPSTEIN, JI ;
WALSH, PC ;
CARMICHAEL, M ;
BRENDLER, CB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05) :368-374